Jump to content

Talk:Bobby Sheng

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
[edit]

Hello fellow Wikipedians,

I have just modified 3 external links on Bobby Sheng. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at {{Sourcecheck}}).

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

  • If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
  • If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 04:26, 5 November 2016 (UTC)[reply]

  • Specific text to be added or removed: Hi fellow wikipedians, I've gathered latest informations on developments of Sheng's company and his philanthropy activities. Hopefully someone can pick up and rewrite to fill in these updates-

Bobby Sheng

Bobby Sheng (Chinese: 盛保熙; pinyin: Sheng Bao Xi; born April 1972) is a Taiwanese-American businessman, entrepreneur, philanthropist, record producer, and film producer. He is the founder, president and CEO of Bora Pharmaceuticals 保瑞藥業,[1] currently the largest pharmaceutical company in Taiwan.[2]

 Not done for now: it's not clear what changes you want to be made. Please mention the specific changes in a "change X to Y" format. PK650 (talk) 01:28, 2 February 2025 (UTC)[reply]

Early life and education

[edit]

Bobby Sheng grew up in Huntington Beach, California, in a family deeply rooted in the pharmaceutical industry. His father owned a pharmaceutical company, Hoan Pharmaceuticals, in Taiwan, and during summers, Bobby worked in the company’s warehouse or office.[3] At his father's encouragement, he pursued economics at the University of California, Berkeley.[4] However, while still in university, his father fell ill, and Bobby, at the age of 22, had to return to Taiwan to work in the family business.[5]

Career

[edit]

Pharmaceutical Leadership

At Hoan, Bobby worked with family members and consultants as Company President[6].

Ventures Beyond Pharma

Sheng explored ventures in other industries, including marketing, media, and technology. During the dot-com bubble, he gained experiences in mergers and acquisitions by co-founding TheOne.com and then consolidating five struggling tech companies into a single, successful entity.[7]

His passion for music led him to establish Machi Entertainment a digital-first record label in Asia with Taiwan entertainer Jeff Huang and Korean producer Jay Chong[1] recognizing the growing demand for digital music amidst declining CD sales and rampant piracy. Sheng served as producer, financier and executive.

Bora Pharmaceuticals 2007-2016

Sheng later shifted his focus back to pharmaceuticals, recognizing the need to expand beyond Taiwan’s saturated market[7] even though Hoan had already been known as major CNS/Neurology product distributor in Taiwan with Lexapro and Lendormin as its blockbusters in local market[8]. Inspired by the global nature of the pharmaceutical industry, he spearheaded a strategic pivot toward contract manufacturing and independently founded Bora Pharmaceuticals.[9]

To convince new recruits and new investors, he distributed copies of the business fable “Who Moved My Cheese?” emphasizing that success requires adapting to change. “The cheese has moved on,” he declared[10]. This led to the acquisition of Bora’s first manufacturing facility, in Tainan, Taiwan, from a longstanding Japanese partner Eisai in 2013[11] and started Bora Pharmaceutical’s focus on contract drug development and production for international markets.

Since April 2017, Bora Pharmaceuticals has been a publicly traded company on the Taiwan Stock Exchange.

Bora Pharmaceuticals CDMO expansion 2018-2022

Bora expanded its small molecule CDMO business by acquiring production sites in Zhunan, Taiwan (ex-Impax/Amneal) in 2018, and in Mississauga, Canada (ex-GSK) in 2020, accelerating Bora’s entry into the North American market. The Canadian facility was integrated with Bora and succesfully passed inspections regardless of obstacles stemming from the Covid epidemic[12]. At this stage, Sheng’s company services patients from over 100 countries[13].

Bora has leveraged scalability and technical skills to maintain strong relationships with key accounts[14] [15] while advancing specialty generic drug production. Commenting on his growth strategy, CFO Alice Wang said[16] “Prior to acquiring Tainan site from Eisai, Bora was merely a pharmaceutical distributor with no manufacturing experience. The first deal provided Bora with the foundation to develop manufacturing capabilities and production management mindset, making later deals possible and successful.”

"International pharmaceutical companies are less likely to consider outsourcing orders to small manufacturers," analyzed Hui-Chin Tseng, Honorary Deputy Managing Partner at PwC Taiwan. She explained that focusing on contract manufacturing has the advantage of providing stable revenue streams; however, to secure contracts, a CDMO’s production capacity and scale must also align with international standards. “The faster the scale and standards expand and improve, the better.”[17]

Bora Pharmaceuticals Dual Engine Strategy 2022 Till Present

2022 marked Bora's entry into the large molecule CDMO space with the establishment of Bora Biologics, anchored by the acquisition of Eden Biologics[18]. Bora acquired TWi Pharmaceuticals, an US generics company based in Taiwan. The merger brought high-value ANDA assets and added two oral solid dosage (OSD) and one ophthalmic manufacturing facility to its CDMO production capabilities. The successful U.S. launch of TWi’s Dexlansoprazole DR[19], recognized by IQVIA as one of 2023’s top launches, solidified Bora’s footprint in the U.S..

In 2024, Bora Pharmaceuticals produced 2.8 billion doses and enabled a total of 96 commercial products[20]. Operating under a "Dual Engine" model[21] that integrates CDMO and commercial expertise, Bora’s CDMO business unit empowers pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs[22]. Simultaneously, Bora commercial RX business unit continues to invest in R&D Partnerships and sales, focusing on niche and rare disease markets[23].

Sheng continues to position Bora in growth areas such as sterile injection and large molecule CDMO[24]. In 2024, Bora acquired a Maryland-based facility (formerly Emergent)[25] and invested in biosimilar company Tanvex[26].

Awards and honors

[edit]

In 2020 Sheng received the CEO of the Year at the CPhl Awards.[27]

In addition Bora Pharmaceuticals has received many honors. In both 2019 and 2024[28], it received recognition at HR Asia's Best Companies to Work for in Taiwan awards. In 2024, Bora also received HR Asia's Most Caring Company award. In 2023, Bora Pharmaceuticals received the Most Outstanding Company of the Year award from Bio-Asia Taiwan, where Sheng was recognized by Taiwan President Tsai Ing-Wen. In 2024, Bora Pharmaceuticals won the Presidential Innovation Award[29], and donated the prize money to those impacted by earthquakes in Hualien.

Philanthropy and Social Impact

[edit]
  1. Since 2021, Sheng has been a Partner in Taishin Healthcare Limited Partnership, a private equity fund focusing on identifying contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) that align with emerging global trends[30].
  2. Sheng is on the advisory board for Berkeley’s College of Chemistry[31] and has multiple philanthropic endeavors with various universities[32].
  3. In 2023, Sheng founded the John Wayne Sheng Foundation, which supports the education of adolescent depression and anxiety[33].

References

[edit]
  1. ^ "領導團隊 – 保瑞集團".{{cite web}}: CS1 maint: url-status (link)
  2. ^ "保瑞、美時2024年營收寫新猷". Bora Pharmaceuticals.{{cite web}}: CS1 maint: url-status (link)
  3. ^ "盛保熙 積極併購放眼國際". 工商時報.
  4. ^ "leadership". UC Berkeley International Alumni Network.{{cite web}}: CS1 maint: url-status (link)
  5. ^ "Bora's CEO, Bobby Sheng's interview with The Medicine Maker magazine". BORA CDMO.{{cite web}}: CS1 maint: url-status (link)
  6. ^ "盛保熙 積極併購放眼國際". 工商時報.{{cite web}}: CS1 maint: url-status (link)
  7. ^ a b "保瑞打造CDMO王國的成功經營心法". 台灣產業創生平台.{{cite web}}: CS1 maint: url-status (link)
  8. ^ "和安行股份有限公司". 123求職網.{{cite web}}: CS1 maint: url-status (link)
  9. ^ "Bora's CEO, Bobby Sheng's interview with The Medicine Maker magazine". BORA CDMO.{{cite web}}: CS1 maint: url-status (link)
  10. ^ "Bora's CEO, Bobby Sheng's interview with The Medicine Maker magazine". BORA CDMO.{{cite web}}: CS1 maint: url-status (link)
  11. ^ "保瑞打造CDMO王國的成功經營心法". 台灣產業創生平台.{{cite web}}: CS1 maint: url-status (link)
  12. ^ "保瑞藥業加拿大廠 成功完成加拿大衛生部查核". 中華民國製藥發展協會.{{cite web}}: CS1 maint: url-status (link)
  13. ^ "Bora Pharmaceuticals with CDMO operations facilities in North America and Asia strives to advance Taiwan's biopharmaceutical excellence". Bio Spectrum.{{cite web}}: CS1 maint: url-status (link)
  14. ^ "保瑞與衛采再續五年約，營運添柴火". 中華民國製藥發展協會.{{cite web}}: CS1 maint: url-status (link)
  15. ^ "大報喜！ 保瑞8.3億 收購GSK加國藥廠". 中華民國製藥發展協會.
  16. ^ "「南部小藥廠要來併我們？」保瑞9年6併，如何收服兩倍大美商？". 天下雜誌.{{cite web}}: CS1 maint: url-status (link)
  17. ^ "「南部小藥廠要來併我們？」保瑞9年6併，如何收服兩倍大美商？". 天下雜誌.{{cite web}}: CS1 maint: url-status (link)
  18. ^ "保瑞攜手趙宇天15億收購伊甸生醫CDMO廠跨足大分子生物藥". 全球醫療採購網.{{cite web}}: CS1 maint: url-status (link)
  19. ^ "保瑞「這顆」學名藥大吞市占率，原廠反而節節敗退剩不到2成". 今周刊.{{cite web}}: CS1 maint: url-status (link)
  20. ^ "Bora Company Presentation at 43rd Annual J.P. Morgan Healthcare Conference". BORA CORP.{{cite web}}: CS1 maint: url-status (link)
  21. ^ "JPM 2024: Taiwan's Pharma Giant Bora Pharmaceuticals Climbing US Pharmaceutical Summit". Gene Online.{{cite web}}: CS1 maint: url-status (link)
  22. ^ "Making Success More Certain". BORA CDMO.{{cite web}}: CS1 maint: url-status (link)
  23. ^ "Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals". Upsher Smith Laboratories.{{cite web}}: CS1 maint: url-status (link)
  24. ^ "Pharmaceutical CDMO Industry is Rising Rapidly Up to USD 295.95 Bn by 2033". Bio Space.{{cite web}}: CS1 maint: url-status (link)
  25. ^ "Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million". BioSpace.{{cite web}}: CS1 maint: url-status (link)
  26. ^ "Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals". BioSpace.{{cite web}}: CS1 maint: url-status (link)
  27. ^ "Bora Pharmaceuticals' Bobby Sheng Wins 'CEO of the Year' at the CPhI Pharma Awards". BioPharm International.{{cite web}}: CS1 maint: url-status (link)
  28. ^ "HR Asia". HR Asia.{{cite web}}: CS1 maint: url-status (link)
  29. ^ "第六屆「總統創新獎」獲獎名單公布 元太科技、保瑞藥業、嘖室、林本堅、劉耕名奪得殊榮". 經新聞.{{cite web}}: CS1 maint: url-status (link)
  30. ^ "Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan". BORA CORP.{{cite web}}: CS1 maint: url-status (link)
  31. ^ "College of Chemistry". UC Berkeley.{{cite web}}: CS1 maint: url-status (link)
  32. ^ "Bobby Sheng envisions a future of collaboration at the College of Chemistry". UC Berkeley Inspire.{{cite web}}: CS1 maint: url-status (link)
  33. ^ "【財團法人臺北市保瑞盛維恩基金會】《家有青少年相談室》線上課程+個人回饋". 張老師文化.{{cite web}}: CS1 maint: url-status (link)


Taiwan

This Taiwanese business–related biographical article is a stub. You can help Wikipedia by expanding it.

  • Reason for the change: to reflect business developments and his role as the founder in the copmany
  • References supporting change: provided in the first bullet point

Diyanc (talk) 16:35, 1 February 2025 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Bobby_Sheng&oldid=1273381930"